Neuro-oncology | Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF

Recurrent tumor and treatment-induced effects have different MR signatures in contrast enhancing and non-enhancing lesions of high-grade gliomas.

Neuro-oncology

Cluceru J, Nelson SJ, Wen Q, Phillips JJ, Shai A, Molinaro AM, Alcaide-Leon P, Olson MP, Nair D, LaFontaine M, Chunduru P, Villanueva-Meyer JE, Cha S, Chang SM, Berger MS, Lupo JM

Na?/K?-ATPase �2-subunit (AMOG) expression abrogates invasion of glioblastoma-derived brain tumor-initiating cells.

Neuro-oncology

Sun MZ, Kim JM, Oh MC, Safaee M, Kaur G, Clark AJ, Bloch O, Ivan ME, Kaur R, Oh T, Fouse SD, Phillips JJ, Berger MS, Parsa AT

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas.

Neuro-oncology

Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H

TMOD-28. NEW APPROACHES FOR ELUCIDATING MEDULLOBLASTOMA DEVELOPMENT VIA HINDBRAIN BLASTOCYST COMPLEMENTATION.

Neuro-oncology

Christin Schmidt, Annika Carlson, William Weiss, Bjoern Schwer

Targeting Wee1 for the treatment of pediatric high-grade gliomas.

Neuro-oncology

Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, Haas-Kogan DA

EPCO-12. IN VIVO PERTURB-SEQ DEFINES BIOLOGICAL DRIVERS AND THERAPEUTIC VULNERABILITIES UNDERLYING RADIOTHERAPY RESISTANCE IN GLIOBLASTOMA.

Neuro-oncology

John Liu, Joanna Pak, Christopher Zou, Sixuan Pan, Emily Payne, Kyla Foster, Katie Lin, Tim Casey-Clyde, Kyounghee Seo, Thomas O'Loughlin, David Wu, Daniel Lim, Harish Vasudevan, Aaron Diaz, Tomoko Ozawa, Mitchel Berger, John de Groot, William Weiss, Luke Gilbert, David Raleigh

MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence.

Neuro-oncology

Mathur R, Zhang Y, Grimmer MR, Hong C, Zhang M, Bollam S, Petrecca K, Clarke J, Berger MS, Phillips JJ, Oberheim-Bush NA, Molinaro AM, Chang SM, Costello JF

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Neuro-oncology

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S

EPCO-39. CLARIFYING THE MOLECULAR CONSEQUENCES OF ONCOGENIC MUTATIONS THROUGH MULTISCALE AND MULTIOMIC ANALYSIS OF INDIVIDUAL TUMORS.

Neuro-oncology

Patrick Schupp, Samuel Shelton, Daniel Brody, Rebecca Eliscu, Brett Johnson, Tali Mazor, Kevin Kelley, Matthew Potts, Michael McDermott, Eric Huang, Daniel Lim, Russell Pieper, Mitchel Berger, Joseph Costello, Joanna Phillips, Michael Oldham

Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank.

Neuro-oncology

Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H

Subscribe to Neuro-oncology